BridgeBio Oncology Therapeutics Inc BBOT
$8.09
▼ -4.82%
($-0.41)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$8.50
Prev Close
$8.50
Day Range
$8.01 – $8.59
52W Range
$7.00 – $14.87
Market Cap
$648.07M
Beta
0.80
EPS (TTM)
$-2.30
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-02-09 |
| Shares Out. | 80,110,000 |
| Website | bbotx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 106 |
| Net Income | -$42.1M |
| Free Cash Flow | -$149.7M |
| Total Assets | $417.6M |
| Total Liabilities | $45.4M |
| Equity | $372.3M |
About BridgeBio Oncology Therapeutics Inc
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
BridgeBio Oncology Therapeutics Inc is a publicly traded company under the ticker symbol BBOT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)